Technologies

We developed a procedure aimed at simultaneously treating thousands of C.elegans model organisms, from eggs to old adult, in liquid, in 96- or 384-well plates. This procedure can be used to perform drug and toxicological screening of millions of compounds, in very small volumes and on millions of animals. Thanks to easy handling, semi-automatic analysis can be performed using plate readers or High Content Screening instruments.

Characterization of authenticity of honey by the combined use of high resolution Nuclear Magnetic Resonance spectroscopy (NMR) and multivariate statistical analysis. Particularly, based on our database, different characterization involving authentication assessment, like botanical or geographical origin determination are possible. Moreover, it is possible to detect saccharides addictions like inulin, corn/malt syrups, and inverted sugar. Finally, it is possible to distinguish the Italian biological honey from the conventional one.

Our idea come from the improving of the traceability technique in agro-food fisheries industries through the application of omics technologies in microbiota studies.  These latter would be capable of exploiting the huge pool of biological molecules contained in fishery resources (e.g. nucleic acids, proteins, metabolites) and use them as a powerful tools for the identification and reconstruction of fishery history, from the sea to the table.

22q11.2DS(DGS) deletion syndrome is a rare and phenotypically variable multiorgan syndrome, currently without any cure. Our aim is to develop a standardized approach to formulate pharmacological products useful for clinical trials direct to prevent some serious clinical manifestations of adolescence and adulthood, such as neuropsychiatric and musculoskeletal diseases, or to eliminate or improve cardiovascular defects during embryonic development.

The technology based on cell or tissue cultures is very useful for the production of bioactive compounds. These molecules, depending on the class they belong to, can be used in the food, pharmaceutical and cosmetic industry. In particular, the developed technology is addressed to the optimization of bioactive compounds in plant cell/tissue cultures having the biosynthetic pathway of the compound of interest.

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.

Detection devices for the presence of molecules of interest (analytes) enjoyed a renewed burst with the introduction of biological components (biosensors). Their high specificity is often used in various fields, from environmental monitoring and biomedicine to the protection and promotion of agri-food products. However, the high cost of production and the lack of compatibility with mass sampling (high-throughput) sometimes limit their use.

Extracellular vesicles produced by teratocarcinoma cells were isolated and characterized. Functional assays on glioblastoma (GBM) cell cultures showed the inhibitory effect of these vesicles on tumor cell migration, without inducing undesirable effects such as increased cell proliferation or chemotherapy resistance.

Integrative omics has posed new challenges in modern precision medicine, particularly in oncology, including i) the identification of new tumor markers for early, precise, and non-invasive diagnostics, and ii) the discovery of innovative molecular targets for therapeutic applications. Our studies on medulloblastoma, a highly malignant childhood tumor, have contributed to identifying RNA molecules that meet these criteria.

In our recent publication we identified a group of  bladder cancer-specific ncRNA, called T-UCRs that are the most up-regulated in bladder cancer patient samples compared with normal bladder urothelium.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

Mergers e Acquisitions represent important forms of business deals because of the volumes involved in the transactions and the role of the innovation activity of companies. By considering the patent activity of about one thousand companies, we develop a method to predict future acquisitions by assuming that companies deal more frequently with technologically related ones.

An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.

It enables a systemic and evolutionary development of people, organisations and territories by overcoming the criticality of traditional approaches, which get stuck because of rationalistic reductions in complexity, as well as lack of motivation. This responds to the social sustainability needs highlighted by the UN 2030 agenda. The methodology is based on 3 pillars:

The object of the technology is the development of a transferable methodology from the laboratory scale to the pilot scale to be validated in the industrial setting for the treatment of basic waste of natural polymers of agro-food or manufacturing industry.